Cargando…
Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma
BACKGROUND: Immune-related diarrhoea/colitis (ir-D/C) is a common adverse event of immune checkpoint inhibitor (ICI) therapy. Guidelines recommend corticosteroid (CS) treatment; however, the average treatment duration for ir-D/C remains poorly defined. METHODS: All advanced melanoma patients treated...
Autores principales: | Favara, David M, Spain, Lavinia, Au, Lewis, Clark, James, Daniels, Ella, Diem, Stefan, Chauhan, Dharmisha, Turajlic, Samra, Powell, Nick, Larkin, James M, Yousaf, Nadia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348326/ https://www.ncbi.nlm.nih.gov/pubmed/32641348 http://dx.doi.org/10.1136/esmoopen-2019-000585 |
Ejemplares similares
-
How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019) -
New survival standards for advanced melanoma
por: Spain, Lavinia, et al.
Publicado: (2020) -
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
por: Alexander, James L, et al.
Publicado: (2021) -
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection
por: Flynn, Michael, et al.
Publicado: (2018) -
Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
por: Alexander, James L, et al.
Publicado: (2022)